Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W3RW
|
|||
| Former ID |
DCL000570
|
|||
| Drug Name |
MK-2206
|
|||
| Synonyms |
MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rectal adenocarcinoma [ICD-11: 2B92; ICD-10: C50] | Phase 2 | [1], [2] | |
| Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Investigative | [3] | ||
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H21N5O
|
|||
| Canonical SMILES |
C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N
|
|||
| InChI |
1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
|
|||
| InChIKey |
ULDXWLCXEDXJGE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1032349-93-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
56262759, 56394183, 57492690, 103741972, 104148011, 124897541, 124897542, 124897543, 134339130, 134339480, 135692873, 137752525, 137752626, 144116227, 144206919, 152258030, 160645322, 163643092, 164230576, 170466896, 177748733, 180371704, 186009068, 198991166, 202828917, 224709963, 226842086, 248150957, 248783687, 249565628, 251963159
|
|||
| ChEBI ID |
CHEBI:67271
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7945). | |||
| REF 2 | ClinicalTrials.gov (NCT01249105) MK-2206 for Recurrent Malignant Glioma. U.S. National Institutes of Health. | |||
| REF 3 | UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72. | |||
| REF 4 | First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.